120 related articles for article (PubMed ID: 30003571)
1. Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
Linos K; Tafe LJ
Histopathology; 2018 Dec; 73(6):963-968. PubMed ID: 30003571
[TBL] [Abstract][Full Text] [Related]
2. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
4. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
6. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
8. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Toth LN; de Abreu FB; Tafe LJ
Hum Pathol; 2018 Aug; 78():138-143. PubMed ID: 29723602
[TBL] [Abstract][Full Text] [Related]
12. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
14. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
15.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
16. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
Lopez GY; Reitman ZJ; Solomon D; Waldman T; Bigner DD; McLendon RE; Rosenberg SA; Samuels Y; Yan H
Biochem Biophys Res Commun; 2010 Jul; 398(3):585-7. PubMed ID: 20603105
[TBL] [Abstract][Full Text] [Related]
17. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
18. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
20. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
